GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024GlobeNewsWire • Tuesday
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceGlobeNewsWire • 10/02/24
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-MarketGlobeNewsWire • 08/29/24
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-MarketGlobeNewsWire • 08/20/24
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register NowGlobeNewsWire • 08/20/24
GeoVax's stock soars 54% to lead rally in companies developing mpox treatmentsMarket Watch • 08/19/24
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory BoardGlobeNewsWire • 08/08/24
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/06/24
Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee ReviewGlobeNewsWire • 07/31/24
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine CongressGlobeNewsWire • 03/28/24
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing SystemGlobeNewsWire • 03/06/24